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The activation of regulatory peptides by post-translational modification of their biosynthetic precursors is generally thought to occur only in neu- 
roendocrine cells. We have selected clones of Chinese hamster ovary cells, a non-neuroendocrine c ll line, which were transfected with a eukatyotic 
expression vector coding for the precursor for neuropeptide Y. Although the majority of the immunoreactive NPY was found in the form of pro- 
NPY, some degree of intracellular proteolytic processing of the precursor occurred in all clones. Part of the intracellular NPY immunoreactivity 
was even correctly amidated. Extracellular degradation of pro-NPY in the tissue culture medium generated i~uno~acti~ty which corresponded 
in size to NPY. It is concluded that precursor processing can occur in non-neur~nd~~ne cells both as a biological process within the cells and 
as apparent processing, degradation in the tissue culture. medium. 
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1. INTRODUCTION 
In recent years, investigations of post-translational 
modifications of regulatory peptides have changed 
from rather passive descriptions of the natural biosyn- 
thesis towards more active studies using transfection of 
cell lines. New questions concerning e.g. the structure- 
function relationship of precursor molecules can now 
be addressed by expressing the cDNA coding for a pep- 
tide precursor and mutants of this in neuroendocrine 
cell lines. The first transfection experiments with pep- 
tide precursors were performed in COS cells, a non- 
neuroendocrine cell line, using vectors in which the 
cDNA for pre-proins~in was placed under the 
transcriptional control of the SV-40 promoter [1,2]. 
The transfected cells produced proinsulin by transient 
expression of the plasmids. The production of un- 
processed prohormone in non-neuroendocrine cell lines 
was confirmed in transient expression experiments and 
in stably transfected clones of CHO cells for pancreatic 
polypeptide [3], 3T3 cells for somatostatin [4], BHK 
cells for glucagon 151, BSC-40 cells for enkephalin 161, 
and in BHK cells for vasopressin 171. However, in an 
early study, Warren and Shields did observe apparent 
processing of pro-somatostatin in COS cells [8]. 
(CHO) cells to optimize vector constructions, etc. [3]. 
In the present paper, we present evidence for in- 
tracellular cleavage and partial amidation of the NPY 
precursor in stably transfected CHO cells, as well as 
evidence for degradation of the precursor by the tissue 
culture medium. In both cases, the cleavage of the NPY 
precursor mimics the precursor processing of neuroen- 
docrine cells. 
2. MATERIALS AND METHODS 
2.1. DNA consinictions 
The dicistronic mammali~ expression vector ~753 has 4 functional 
elements, as shown in fig.1. These elements were cloned in 
EcoRIlBamHI digested pML [9]. A human ubiquitin gene (Ub C) 
promoter [ 101 was cloned at the 5 ’ -end of the expression unit. (Lamb- 
da)HUbl3 [IO] was digested with XhoI and the resulting 1.5 kb pro- 
moter containing fragment was cloned in SalI digested pBR322 to 
generate pBR322ubi. The 1.5 kb XhoI fragment of the human ubi- 
quitin gene has &#I1 sites just 3 ’ to the initiating methionine codon 
and 0.1 kb 3 ’ to the upstream XhoI site. pBR322ubi was digested with 
Bg!II, then digested with Ba131 to eliminate 6 nucleotides at the 
3 ‘-end of the fragment. Hereby the methionine codon was removed. 
Hind111 linkers were added, and the resulting 1.4 kb promoter frag- 
ment was subcloned in Hind111 digested pIC19R 1111. From such a 
plasmid the ubiq~tin promoter was isolated as a 1.4 kb 
EcoRIlBamHI fragment and used in the construction of ~753. 
As the basis of protein engineering studies on the 
precursor for neuropeptide Y (NPY), we initially used 
the fast growing, non-endocrine Chinese hamster ovary 
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Human NPY cDNA was isolated from pNPY3-75 [12] as a 0.38 kb 
BssHII-/HinfI fragment, treated with the klenow fragment of DNA 
polymerase to repair the staggered ends, and then ligated to BarnHI 
linkers. The resulting 0.38 kb BamHI fragment was used in the final 
construction of ~753. The neomycin phosphotransferase gene from 
pKm2 [13] was isolated as a 1 kb BglII/SmaI fragment. The staggered 
ends at the BglII site were repaired with klenow DNA polymerase, 
and the neogene was subcloned in a HirtdIII digested pIC19R vector 
with repaired ends. From a subclone, the neogene was isolated as a 1 
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kb BumHI/BgfII fragment and used in the construction of ~753. At 
the 3 ‘-end of the construct, the early polyadenylation signal of SV40 
was cloned as a 0.24 kb BumHI/BcII fragment. 
2.2. Transfection procedure 
Chinese hamster ovary (CHO) cells were maintained in RPM1 1640 
containing 10% fetal calf serum (Gibco) with 5% COZ. 1.8 x 106 
cells were seeded in 100 mm Petri discs and the transf~~on was car- 
ried out after 24 h by the calcium phosphate precipitation technique 
[14] using 2 fig pSV*-Neo and 20 fig ~753. Cells were split 1:4 into 
selection media containing 0.8 mg/ml G418 (Sigma) 48 h after 
transfection. Clones were picked after 14 days and propagated in 
selection media. 
2.3. Peptide characterization 
Cells from 150 cm2 confluent flasks were extracted in 2 ml 50% 
(v/v) acetic acid, boiled for 3 min, and sonicated for 15 min in a bath 
sonicator prior to centrifugation at 3 000 x g for 15 min. The super- 
natant was dried in a vacuum centrifuge and reconstituted in assay 
buffer (see later). The protein content of the acetic acid extracts was 
determined using the Bio-Rad protein assay. The tissue culture media 
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Fig. 1. Diagram of the eukaryotic expression vector and of the NPY 
antisera. In the middle is a schematic representation of the cDNA for 
human NPY. Above is shown the primary translation product, 
prepro-NPY, in which NPY is preceded by a 28 amino acid signal- 
peptide and separated from a 30 amino acid C-terminal spacer- 
peptide, C-peptide, by a combined cleavage and amidation site, Gly- 
Lys-Arg (GKR). On top are shown the recognition sites of the two 
NPY antisera used, Ab 337 which reacts both with NPY and pro-NPY 
and Ab 8999 which is specific for the amidated C-terminus of NPY, 
and therefore does not react with precursors for NPY. At the bottom 
is shown the expression vector, ~753, in which the NPY cDNA is plac- 
ed under the transcriptional control of the human ubiquitin (UbC) 
promotor as described in detail in the text. 
were either assayed directly or aliquots (usually 10 ml) were 
precipitated with 4 vols of acetone. The precipitate was dried under 
nitrogen and reconstituted in 5% (v/v) formic acid (Merck) contain- 
ing 10 mg/l of bovine serum albumin. The human neuroblastoma cell 
line, SH-SYSY, was used as a source of pro-NPY, as described 
elsewhere [IS]. 
2.3.1. Radioimmunoassays 
The recognition site for the two NPY antisera used are indicated in 
fig.1 and the radioimmunoassays have been described in detail 
previously [IS]. Rabbit antiserum NPY-8999, raised against Cys-NPY 
(31-36)-peptide coupled to BSA with maleimidobenzoyl-iV- 
hydroxysuccinimide, is highly specific for the C-terminal part of 
NPY, including the amide function, Rabbit antiserum NPY-337, rais- 
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Fig.2. Gel filtration profile of NPY immunoreactivity extracted from 
4 different clones of transfected CHO ceils. NPY immunoreactivity 
was detected using Ab 337. The elution positions of pro-NPY (open 
arrow) and NPY (closed arrow) are indicated. 
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ed against NPY coupled to BSA with c~b~~de is not dependent 
on the amide function but does reco8nise the C-terminal part of NPY, 
as it reacts equally well with e.g. NPY (13-36)-peptide. Radio- 
iodinated porcine NPY was prepared and purified as described 
previously [16]; [12~t-~‘lmonoiodo NPY was used as tracer in the 
assay employing antibody NPY-8999. The assays were performed in 
a total of 0.6 ml in 0.05 M sodium phosphate buffer, pH 7.4, contain- 
ing 2.5 g/l of BSA and 0.5 mM thiomersalate. Incubation was per- 
formed at 4°C for 2 days without and 1 day with tracer. Antibody- 
bound and free tracer were separated by plasma-coated charcoal. 
2.3.2. Chromatography 
Cell or media extracts were applied to Sephadex G-50 superfine col- 
umns (1.6 x 95 cm) eiuted with 5% (v/v) formic acid cont~ing 10 
mg/l BSA at 4*C. Fractions were dried in a vacuum centrifuge and 
reconstituted in assay buffer. 
3. RESULTS 
Stable clones of the CHO cells producing between 
100 and 5000 pmol/I immunoreactive NPY per 24 h per 
2.5 x 10' cells in 10 ml of medium, were selected. 
Chromatographic characterization of the NPY im- 
munoreactivity extracted from 4 different clones, which 
contained between 180 and 475 fmol of NPY per 
5 x 10’ cells are shown in fig.2. As expected in these 
non-neuroendocrine cells, the majority of the NPY was 
found in the form of the unprocessed propeptide. 
However, some degree of intracellul~ cleavage of the 
precursor was observed in all clones. Between 5% and 
45% of the NPY immunoreactive material was eluted 
corresponding to NPY or intermediary forms (fig.2). 
For a given clone, the amount of intracellular process- 
ing was constant over several passages. As shown for 
cell line CHO-BW19 in fig.3, a major portion of the 
NPY immunor~ctivity, which in apparent size cor- 
responded to NPY l-36, was amidated as judged by its 
reactivity with the amide-specific assay. Thus, in 
transfected CHO clones, limited proteolysis of pro- 
NPY and amidation of NPY takes place to a variable, 
albeit limited degree. 
When the NPY immunoreactivity from the tissue 
culture medium of the same CHO clones was charac- 
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Fig.3. Gel filtration profile of NPY immunor~ctivity extracted from 
the clone CHOBW19. To get enough material for assaying without 
overloading the column, fractions from two consecutive gel filtrations 
were pooled and assayed using both Ab 337 (+---o) and Ab 8999 
(o--o). which was used for ra~oimmunoassay. 
Fig.4. Gel filtration profile of NPY immunoreactivity extracted from 
the tissue culture medium from 4 different clones of transfected CHO 
cells. NPY imm~or~ctivity was determined with Ab 337. The ehr- 
tion position of pro-NPY (open arrow) and NPY (closed arrow) are 
indicated. Variable amounts of apparent immunoreactivity are 
observed in the void volume dependent on the amount of material 
terized, a more uniform pattern appeared, In this case 
the immunoreactivity was almost equally distributed 
between molecular forms corresponding in size to the 
propeptide and to a form eluting just before standard 
NPY (fig.4). Thus NPY immunoreactivity of an ap- 
parent size corresponding approximately to NPY 
precursor, e.g. CHO-BW20 and CHO-BW7 (fig.2 and 
4). This discrepancy indicated that the cleavage of the 
pro-NPY could occur extracellularly. When pro-NPY, 
isolated and purified from a human neuroblastoma cell 
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pltld/l 
CHO-BW 13 
80 
A 
180- 
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Fig.% Degradation of pro-NPY by tissue culture medium. Gel filtered 
pro-NPY isolated from a human neurobl~toma cell line, SH-SYSY, 
was incubated with tissue culture medium, supplemented with 15% 
foetal calf serum, and either analyzed immediately (control) or after 
24 h of incubation (+ medium incubation). 
line SH-SYSY [15], was incubated overnight with un- 
conditioned tissue culture medium only, it was found 
that the medium degraded the precursor to a moleclar 
form of immunoreactive NPY eluting on the G-50 col- 
umns right before NPY (fig.5). Only a minimal part of 
this material, which eluted as several molecular species 
both on HPLC and on isoelectric focusing was 
amidated, indicating different kinds of proteolytic 
degradation (data not shown). 
4. DISCUSSION 
In the present study, limited processing of a peptide 
precursor was observed in transfected non- 
neuroendocrine cells, both as a biological process 
within the cells and as a trivial problem in the tissue 
culture medium. Such processing and degradation 
should be taken into account when precursor processing 
is being studied, even in neuroendocrine cells. 
A variable amount of the NPY immunoreactivity 
found in the transfected CHO cells corresponds in size 
to authentic NPY, and some of it even appears to be 
amidated. These findings indicate that precursor pro- 
cessing can occur in non-neuroencodrine CHO cells. It 
was previously thought that the amidating enzyme was 
expressed only in true neuroendocrine cells. However, 
northern blot analysis has demonstrated that mRNA 
for the enzyme also is found in several non-endocrine 
tissues and cell lines, e.g. 3T3 cells (Betty Eipper, per- 
sonal communication). It should also be noted, that 
probably all cells in their secretory pathway, con- 
ceivably in the Golgi complex, have proteases with 
specificities for basic residues. Such proteases which 
cleave at sites of multiple basic residues are involved in 
e.g. the processing of the precursor for the insulin 
receptor [17], and in the processing of other normal 
membrane proteins and e.g. viral envelope proteins 
[ 181. Recently it has been suggested that the processing 
of proinsulin, at least at one of the processing sites, 
starts already in the Golgi area of the cell [ 191. It is like- 
ly that certain peptide precursors, like pro-NPY, pro- 
somatostatin, and pro-PTH are more susceptible to 
such proteolysis than other precursors. In the case of 
pro-PTH, the small 6 amino acid propeptide is cleaved 
at the tri-basic processing site e.g. in transfected 3T3 
fibroblasts 1201. The degree of processing of pro- 
somatostatin in non-endocrine cells can be increased by 
changing the Arg-Lys sequence to Lys-Arg or Arg-Arg 
by site-directed mutagenesis [21]. 
NPY immunoreactivity of a size comparable to NPY 
was observed in the media from the transfected CHO 
cells. Most of this results from extracellular processing 
of pro-NPY, and at least some of the proteolytic en- 
zymes appeared to be present in the unconditioned 
tissue culture medium. No attempt was made in the pre- 
sent study to define precisely where the cleavages of the 
precursor occurred. There are several possible cleavage 
sites in the precursor of these, the LYS~~ and Arg39, the 
natural processing site of pro-NPY, and the Arg33 and 
Arg3’ in the NPY sequence itself, would ail be good 
targets for trypsin-like enzymes. Cleavage at any of 
these sites could generate peptides which would elute on 
both gel filtration and HPLC with the unhomogeneous 
immunoreactivity from the transfected CHO cell 
media. The sequence, Arg3S-Tyr36, for example, is 
known to be a very susceptible site for tryptic cleavage 
in vitro (unpublished observations). 
Although some of the NPY precursor is processed in 
the CHO cells, most of the NPY remains in the form of 
the unprocessed prohormone. In contrast to this rather 
limited processing, a very efficient processing of pro- 
NPY to amidated NPY occurs in transfected cor- 
ticotrophe cells (AtT-20 [22] and in transfected in- 
sulinoma (RIN), neuroblastoma (NBl), and medullary 
thyroid carcinoma cells (CA-77)*. 
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